Carfilzomib · Blood advances
Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.
2026 May 12
Open attributed record →PubMed publication type · D017426
20 selected PubMed bibliographic records classified as Clinical Trial, Phase I. The classification is supplied by PubMed and does not rate article quality, findings, safety, or effectiveness.
20 selected records.
14 connected profiles.
17 distinct venues.
Attributed bibliography
Carfilzomib · Blood advances
2026 May 12
Open attributed record →Orforglipron · Diabetes, obesity & metabolism
2026 04 17
Open attributed record →Motixafortide · The oncologist
2026 Mar 09
Open attributed record →Eloralintide · Diabetes, obesity & metabolism
2026 01 20
Open attributed record →Carfilzomib · Leukemia & lymphoma
2025 05 21
Open attributed record →Carfilzomib · Blood advances
2023 Oct 10
Open attributed record →Carfilzomib · Targeted oncology
2023 08 26
Open attributed record →Carfilzomib · Blood advances
2023 Apr 11
Open attributed record →Abaloparatide · Clinical drug investigation
2021 02 27
Open attributed record →Lutetium Lu 177 dotatate · Journal for immunotherapy of cancer
2020 Jul
Open attributed record →Bivalirudin · Pharmaceutical research
2019 08 08
Open attributed record →Pasireotide · Clinical genitourinary cancer
2018 02 13
Open attributed record →Pasireotide · Investigational new drugs
2015 08 16
Open attributed record →Tesamorelin · Clinical pharmacokinetics
2015 Mar
Open attributed record →Pasireotide · Cancer chemotherapy and pharmacology
2013 05 17
Open attributed record →Eptifibatide · British journal of haematology
2007 10 03
Open attributed record →Icatibant · The Journal of allergy and clinical immunology
2007 04 05
Open attributed record →Enfuvirtide · The Pediatric infectious disease journal
2004 Dec
Open attributed record →GHRP-2 · The Journal of clinical endocrinology and metabolism
1998 Apr
Open attributed record →Melanotan II · Life sciences
1996
Open attributed record →